RegulatoryMay 1, 2026, 04:31 PM
Celularity Regains Nasdaq Compliance; Files 2025 Form 10-K
AI Summary
Celularity Inc. announced it has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and has regained compliance with Nasdaq Listing Rule 5250(c)(1). This resolves a previous non-compliance notification received on April 16, 2026, due to the delayed filing. The company also highlighted strategic actions, including out-licensing its biomaterials portfolio, realigning non-core personnel, and significantly reducing recorded liabilities by approximately $13 million, to strengthen its balance sheet and focus on core longevity and cell therapy platforms.
Key Highlights
- Celularity filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
- The company regained compliance with Nasdaq Listing Rule 5250(c)(1).
- Nasdaq confirmed compliance on May 1, 2026, closing the non-compliance matter.
- Reduced recorded liabilities by approximately $13 million.
- Out-licensed biomaterials portfolio and realigned non-core personnel.
- Company will now focus resources on core longevity and cell therapy platforms.
Price Impact
More from CELU